• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Epizyme President of Research and Chief Scientific Officer Robert Copeland to retire

Epizyme President of Research and Chief Scientific Officer Robert Copeland to retire

March 9, 2017
CenterWatch Staff

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapies, has announced that President of Research and Chief Scientific Officer Robert A. Copeland, Ph.D., will be retiring from Epizyme in the second quarter of 2017 to pursue advisory and other opportunities within the industry. Dr. Copeland has served in his role since 2008, and will remain a key advisor to Epizyme following his transition. The company is executing plans for continued growth of its investigational pipeline, with plans to name its next development candidate in 2017 as part of its goal of delivering three new candidates into the clinic by 2020.

“I want to thank Bob for his incredible service and invaluable contributions to Epizyme. During his tenure, we pioneered the development of epigenetic therapies for the treatment of cancer, ultimately resulting in our discovery of three novel epigenetic product candidates to enter clinical development,” said Robert Bazemore, president and chief executive officer, Epizyme. “Bob built a strong team and foundation of scientific capabilities that have positioned us well in our evolution from an early-stage company developing a new class of epigenetic targets into a late-stage clinical development organization. I am delighted that Bob will continue to contribute to Epizyme in an advisory role and wish him the best in his next endeavors. We expect a smooth transition and are confident that the plans we are putting in place will further strengthen and secure Epizyme’s future.”

“I am grateful for my time with Epizyme and am overjoyed by what we have been able to accomplish over the past eight years,” said Robert A. Copeland, Ph.D. “With this incredibly talented team, we have discovered entire new classes of targets for epigenetic medicines and built a deep pipeline of early stage programs that are advancing through internal efforts and various collaborations. I am extremely confident in the potential of tazemetostat, the industry’s most advanced EZH2 inhibitor, and look forward to seeing the results of the clinical translation of this company’s novel science. My advisory role will continue to keep me involved with Epizyme and I wish the company all the best in the next phase of its evolution.” 

“Bob has made tremendous contributions to Epizyme’s vision, platform and innovation since its founding,” said David Mott, chairman of Epizyme’s Board of Directors. “On behalf of the entire Board, I want to extend our collective appreciation to Bob and wish him well.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing